



Department
of Health



Hepatitis C Care Cascade

New York State

February 6, 2019

HCV Care and Treatment Initiative

- Primary care settings: community health centers, hospital-based clinics and drug treatment programs offering primary care
- Goals:
 - Increase the number of people infected with HCV who get linked to care
 - Improve HCV treatment initiation and completion rates
- Core activities:
 - Linkage to care
 - HCV care and treatment
 - HCV treatment adherence
 - Retention in care
 - Supportive services
 - Peer delivered services
- Five year initiative (2015-2020)
- A total of 15 programs funded statewide

Data reporting requirements

- AIDS Institute Reporting System (AIRS)
 - One data system for all AIDS Institute funded contractors
 - A database system for entry of client information and service tracking with reporting capabilities
 - Established to meet HRSA data reporting requirements
- Programs submit client-level data through AIRS
 - Demographics (age, gender, race)
 - HCV risk
 - HIV status
 - Insurance and housing status
 - IDU status
 - Past IDU, Current IDU, No IDU, Unknown
 - Services provided
 - HCV treatment outcomes

HCV Treatment Status			
Date Asked ▼	Initiative	On MAT?	Treatment Initiated?
01/01/2019			

Initiative

Date Asked

Client is: Treatment Naïve Treatment Experienced

Is the patient on Medication Assisted Treatment for substance use? Yes No

- If Yes, which treatment?

 Methadone Buprenorphine (Suboxone, Subutex, Zubsolv) Naltrexone (ReVia, Vivitrol, Depade)

Was HCV Treatment initiated? Yes No

- If "No", select primary reason patient did not initiate treatment...

Reason

- If "Yes", Select 'HCV Treatment Types' ...

HCV Treatment Types:

Treatment Start Date


Treatment End Date

Treatment Outcome


- Advanced Liver Disease
- Alcohol Use
- Client Contemplating Treatment
- Client Refused Treatment
- Co-morbid Condition
- Deceased
- Drug Use
- Homelessness
- Incarcerated
- Insurance Coverage/Cost
- Lost to Follow-up
- Patient Not Ready
- Mental Health Condition
- Prior Authorization Denied
- Prior Authorization Pending
- Unstable HIV

- Completed – Cured
- Discontinued – Medical/Side Effects
- Discontinued – Non adherent
- Discontinued – Other
- Completed – Pending final HCV RNA
- Discontinued – Lost to follow-up
- Completed – Not Cured
- Completed – Unknown – Deceased
- Completed – Unknown – Incarcerated
- Completed – Unknown – Lost to follow-up
- Discontinued – Treatment failure
- Discontinued – Deceased
- Discontinued – Incarcerated
- Discontinued – Patient request

Hepatitis C Care Cascade, 4/2017-3/2018



Reports and Data Briefs



New York State Hepatitis C Care and Treatment Initiative

Data Brief #2, May 2018

- The New York State Department of Health (NYSDOH) Hepatitis C (HCV) Care and Treatment Initiative funds 15 primary care sites throughout NYS to provide linkage to care services along with HCV care, treatment, and supportive services.
- This report highlights outcomes from the Initiative's second year (April 2016 - March 2017).

Program Highlights

1,790 patients enrolled, 81% ever linked to a medical provider, 67% linked within 30 days.

Among those who initiated treatment, 90% completed treatment.
Patients who reported past injection drug use were 1.7 times more likely to complete treatment and be assessed for SVR than patients who currently use drugs.


54% of patients linked to care initiated treatment.
Of those eligible, black patients were 1.5 times more likely to initiate treatment and 1.7 times more likely to complete treatment and be assessed for SVR* than white patients.

97% of patients who initiated treatment and had their final HCV RNA test were cured of HCV.

* SVR (Sustained Virologic Response) is defined as the absence of HCV RNA 12 weeks post treatment completion. Patients who achieve SVR are considered cured of HCV disease.

HCV Care Cascade*

Of 1,790 patients with positive HCV antibody test enrolled:



* Data for patients enrolled in programs from 4/2016 through 3/2017 and extracted from AIDS Institute Reporting System (AIRS) on 2/23/2018. Percent denominators are N from previous bar.

** Patients starting treatment are limited to those with reported positive RNA tests.

Contact: hepatabc@health.ny.gov
 For more information, please visit: health.ny.gov/hepatitis
 Produced: The Office of Program Evaluation and Research
 Date: May 2018